Request Demo
Last update 13 Sep 2025
Meropenem/pribactam
Last update 13 Sep 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with Meropenem/pribactamNCT07089186
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled, Parallel-design Clinical Study to Evaluate the Efficacy and Safety of Meropenem and Pralubactam for Injection in the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections
NCT06633718
A Phase 3,Multicenter, Randomized, Double-Blind, Positive Control，Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Complicated Intra-abdominal Infections
CTR20253255
评价注射用美罗培南普莱巴坦在中国成人健康参与者支气管肺上皮衬液药物浓度及渗透性的单中心、随机、开放的I期临床研究
[Translation] A single-center, randomized, open-label phase I clinical study to evaluate the drug concentration and permeability of meropenem-prelebactam for injection in the bronchopulmonary epithelial lining fluid of healthy Chinese adult participants
100 Clinical Results associated with Meropenem/pribactam
Login to view more data
100 Translational Medicine associated with Meropenem/pribactam
Login to view more data
100 Patents (Medical) associated with Meropenem/pribactam
Login to view more data
100 Deals associated with Meropenem/pribactam
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Complicated urinary tract infection | Phase 3 | China | 12 Apr 2025 | |
| Enterobacteriaceae Infections | Phase 3 | China | 12 Apr 2025 | |
| Hospital acquired bacterial pneumonia | Phase 3 | China | 12 Apr 2025 | |
| Sepsis | Phase 3 | China | 12 Apr 2025 | |
| Ventilator associated bacterial pneumonia | Phase 3 | China | 12 Apr 2025 | |
| Complicated intra-abdominal infection | Phase 3 | China | 14 Nov 2024 | |
| Complicated intra-abdominal infection | Phase 3 | China | 14 Nov 2024 | |
| Carbapenem Resistant Bacterial Infection | Phase 3 | China | 08 Nov 2024 | |
| Carbapenem Resistant Bacterial Infection | Phase 3 | China | 08 Nov 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free